MRI to optimise lung cancer radiotherapy

Not Applicable

• Conditions: ung cancer; Cancer

• Registration Number: ISRCTN10891735
• Lead Sponsor: ewcastle upon Tyne Hospitals NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-18
• Last Update Posted: 22 January 2024
• Study Completion: 2024-08-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Aged 18 and over
2. Able to provide written informed consent to participate in the study
3. English speakers
4. Body weight within minimum and maximum scanner requirements of 50-100 kg
5. Diagnosed with non-small cell lung cancer by the clinical team
6. Planned to receive radical OR high dose palliative radiotherapy (+/- adjuvant chemotherapy or surgery)

Exclusion Criteria

1. Patients below the age of 18 years
2. Patients who are not able or decline to give informed consent to participate in the study
3. Non-English speakers
4. Body habitus incompatible with positioning within the MRI scanner sensor used for 19F-MRI (approximately equivalent to a body circumference > 120cm at chest height, and body mass index > 35 kg/m²)
5. Pregnant or breastfeeding
6. MRI contraindications: incompatible implanted medical device (e.g. cardiac pacemaker), or metallic implants incompatible with MRI
7. Claustrophobia incompatible with MRI

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The percentage of ventilated lung volume (%VV) measured using fluorine MRI study data to characterise the extent of lung ventilation defects in the lungs of lung cancer patients before radiotherapy (single scan, baseline) at one time point<br>

Secondary Outcome Measures

Name	Time	Method
Regional tracer gas wash-in and wash-out rates measured using the fluorine MRI scan, and clinical lung function measured using spirometry at baseline